<br>Alisol B 23-acetate 通过 LXRα/ACAT2 通路激活空肠中的 ABCG5/G8，以缓解卵巢切除的 ApoE-/- 小鼠的动脉粥样硬化,Aging-US

当前位置： X-MOL 学术 › Aging › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Alisol B 23-acetate 通过 LXRα/ACAT2 通路激活空肠中的 ABCG5/G8，以缓解卵巢切除的 ApoE-/- 小鼠的动脉粥样硬化
Aging-US ( IF 3.9 ) Pub Date : 2020-11-25 , DOI: 10.18632/aging.104185
Xi-Chao Yu ₁ , Yu Fu ₁ , Yun-Hui Bi ₁ , Wei-Wei Zhang ₁ , Jun Li ₁ , Tingting Ji ₁ , Ying Chao ₁ , Qing-Hai Meng ₁ , Qi Chen ₁ , Meng-Hua Ma ₁ , Yu-Han Zhang ₁ , Jinjun Shan _{2,

3} , Hui-Min Bian _{1,

4,

5,

6}

Affiliation

植物甾醇已被证明可以改善血脂水平并治疗动脉粥样硬化。本研究调查了植物甾醇 Alisol B 23-acetate (AB23A) 对空肠脂质代谢和动脉粥样硬化的影响。结果表明，灌胃AB23A可以显着减少高脂饮食的去势ApoE ^-/-小鼠空肠中的动脉粥样硬化斑块面积和脂质积累，并改善血浆和空肠的脂质质谱。体外研究表明，AB23A 可以增加暴露于高脂肪浓度的 Caco-2 细胞中的胆固醇流出，并增加 ATP 结合盒转移蛋白 G5/G8 (ABCG5/G8)、肝脏 X 受体 α (LXRα) 的表达。此外，抑制LXRα可以显着消除AB23A减少细胞内脂质积累的活性作用。我们还证实，AB23A 对高浓度脂肪培养的 Caco-2 细胞中的酰基辅酶 A 胆固醇酰基转移酶 2 (ACAT2) 具有负面影响，并且我们发现 AB23A 进一步降低了用 ACAT2 抑制剂pyripyropene 或 ACAT2 处理的细胞中的 ACAT2 表达。用 ACAT2 siRNA 转染。总之，我们证实AB23A可以通过影响LXRα-ACAT2-ABCG5/G8通路来减少空肠中膳食脂质的吸收，并最终发挥抗动脉粥样硬化作用。

"点击查看英文标题和摘要"

Alisol B 23-acetate activates ABCG5/G8 in the jejunum via the LXRα/ACAT2 pathway to relieve atherosclerosis in ovariectomized ApoE-/- mice

Phytosterols have been shown to improve blood lipid levels and treat atherosclerosis. This research investigated the effects of phytosterol Alisol B 23-acetate (AB23A) on jejunum lipid metabolism and atherosclerosis. The results show that intragastric administration of AB23A can significantly reduce atherosclerotic plaque area and lipid accumulation in the jejunum of ovariectomized ApoE^-/- mice fed a high-fat diet and can also improve the lipid mass spectra of the plasma and jejunum. In vitro studies have shown that AB23A can increase cholesterol outflow in Caco-2 cells exposed to high fat concentrations and increase the expression of ATP-binding cassette transfer proteins G5/G8 (ABCG5/G8), the liver X receptor α (LXRα). Furthermore, inhibition of LXRα can significantly eliminate the active effect of AB23A on decreasing intracellular lipid accumulation. We also confirmed that AB23A has a negative effect on Acyl-CoA cholesterol acyltransferase 2 (ACAT2) in Caco-2 cells cultured in the high concentrations of fat, and we found that AB23A further reduces ACAT2 expression in cells treated with the ACAT2 inhibitor pyripyropene or transfected with ACAT2 siRNA. In conclusion, we confirmed that AB23A can reduce the absorption of dietary lipids in the jejunum by affecting the LXRα-ACAT2-ABCG5/G8 pathway and ultimately exert an anti-atherosclerotic effect.

更新日期：2021-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南